Recent research have focused on the intersection of GLP|GIP|GCGR activator therapies and DA signaling. While GLP stimulators are widely employed for managing type 2 diabetes, their emerging consequences on motivation circuits, specifically governed by dopaminergic systems, are gaining substantial